NexImmune, Inc.
DelistedCIK 1538210fmd_02FYAW0ZKGM89T82DF04V5TBBEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2024, 18 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 |
| Research and development | 18 | 37 | 47 | 19 |
| Total operating expenses | 28 | 53 | 63 | 33 |
| Operating income | (28) | (53) | (63) | (33) |
| Interest expense | 2 | 1 | 0 | – |
| Interest and investment income | 0 | 0 | 1 | 1 |
| Other non-operating income (expense) | (2) | 2 | 1 | 1 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (30) | (51) | (63) | (32) |
| Net income to common shareholders | (33) | (51) | (63) | (32) |